The BLA acceptance with Priority Review for z-rostudirsen is the primary catalyst, setting up a binary PDUFA event in January 2027. The $431M offering provides ample cash through 2028 but dilutes existing holders by ~13%. Watch for topline ACHIEVE data in Q1 2027 for DM1, which could further de-risk the pipeline. The stock may trade on regulatory milestones rather than quarterly financials.
Drugs in focus
DYN drug pipeline →z-rostudirsen
▲ Bullish Named in this press release- Impact
- Phase
- Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing
- Time to market
- Potential U.S. launch in Q1 2027 if approved — BLA is under FDA Priority Review with a PDUFA target action date of January 21, 2027 (accelerated approval based on dystrophin as a surrogate endpoint).
- Next catalyst
- PDUFA date · Jan 21, 2027 66d
What to watchThe January 21, 2027 PDUFA is the binary to trade: approval odds look favorable (Priority Review, positive Phase 1/2 data, dystrophin surrogate endpoint), but an Accelerated Approval tied to a surrogate plus an unfinished confirmatory trial (FORZETTO) leaves room for a surprise CRL. Watch for an FDA Advisory Committee date in Q4 2026, the Q3 2026 earnings call for any label/launch commentary, and note the heavy 10b5-1 insider selling and ~57% weighted short-volume ratio as overhangs into the decision.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 30 $25.73entry
- T+1 · 4mo ago −2.14%α −2.84% · $25.18
- T+5 · 3mo ago +0.58%α −3.04% · $25.88
- T+20 · 3mo ago +1.40%α −2.57% · $26.09
- T+60 · 25d ago −39.29%α −41.76% · $15.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dyne Therapeutics reported Q2 2026 net loss of $1.08 per share, slightly narrower than the $0.97 loss in Q2 2025 but above the consensus estimate of -$0.75. The key catalyst is the FDA acceptance of the BLA for z-rostudirsen in DMD with Priority Review and a PDUFA date of January 21, 2027, alongside completion of enrollment in the ACHIEVE trial for DM1. The company also completed a $431M public offering and expanded its debt facility to $400M, extending cash runway into Q2 2028.
Key Financial Metrics
Key Facts
- BLA for z-rostudirsen (exon 51 DMD) accepted with Priority Review; PDUFA date January 21, 2027
- Completed enrollment of 71 participants in ACHIEVE registrational expansion cohort for DM1; topline data Q1 2027
- IND cleared for DYNE-302 in FSHD; Phase 1 trial planned
- Completed $431M public offering (21M shares at $20.50) in July 2026
- Expanded Hercules debt facility to $400M
- Cash position $898.5M at June 30, 2026; cash runway into Q2 2028
- Net loss $178.6M ($1.08/share) vs $110.9M ($0.97/share) in Q2 2025
Financial Impact
EPS beat consensus by $0.02 (2.6%), but net loss widened 61% YoY to $178.6M due to increased R&D and G&A spend ahead of potential commercial launch
Risk Factors
- PDUFA delay or Complete Response Letter for z-rostudirsen
- Dilution from $431M offering (21M new shares)
- ACHIEVE topline data miss in Q1 2027
- R&D spend continues to rise without near-term revenue
- Competition from other DMD exon-skipping therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3335623 |
Track record
54 reports on DYN
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers